NEW YORK, July 17, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Agilent Technologies Inc. (NYSE: A), Organovo
Holdings Inc. (AMEX: ONVO), Biocept Inc. (NASDAQ: BIOC), Novadaq
Technologies Inc. (NASDAQ: NVDQ), and ICON Public Limited Company
(NASDAQ: ICLR). Free research report on Agilent Technologies can be
accessed at
https://www.EquityResearchInstitute.com/reports?keyword=A On
Thursday, July 16, 2015, the NASDAQ
Composite ended at 5,163.18, up 1.26%, the Dow Jones Industrial
Average advanced 0.39%, to finish the day at 18,120.25, and the
S&P 500 closed at 2,124.29, up 0.80%. The gains were broad
based as eight out of nine sectors ended the session in positive.
Register for your complimentary reports at the links given below.
Agilent Technologies Inc.'s stock edged 0.52% higher, to close
the day at $40.34. The stock recorded
a trading volume of 1.83 million shares, below its three months
average volume of 2.43 million shares. Over the previous three
months and since the start of this year, Agilent Technologies
Inc.'s shares have fallen by 6.23% and 0.73%, respectively.
However, the stock has advanced 1.64% in the last one month. The
company's shares are trading 0.44% below their 200-day moving
average. Additionally, Agilent Technologies Inc. traded at a PE
ratio of 37.70 and has a Relative Strength Index (RSI) of 52.90.
Sign up and read the free notes on A at:
https://www.EquityResearchInstitute.com/reports?keyword=A
On Thursday, shares in Organovo Holdings Inc. recorded a trading
volume of 1.21 million shares, lower than their three months
average volume of 1.62 million shares. The stock ended the day
1.03% higher at $3.93. Organovo
Holdings Inc.'s stock has plummeted 26.13% in the last one month,
16.74% in the previous three months and 45.79% on YTD basis. The
company is trading below its 50-day and 200-day moving averages by
13.36% and 28.87%, respectively. Furthermore, shares of Organovo
Holdings Inc. have an RSI of 45.13. The complimentary notes on ONVO
can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ONVO
Biocept Inc.'s stock lost 1.82%, to close Thursday's session at
$2.70. The stock recorded a trading
volume of 0.32 million shares, below its three months average
volume of 1.68 million shares. Over the previous three months and
since the beginning of 2015, Biocept Inc.'s shares have advanced
13.45% and 8.87%, respectively. However, the stock has lost 10.89%
in the last one month. The company is trading 6.94% and 2.46% below
its 50-day and 200-day moving averages, respectively. Furthermore,
Biocept Inc.'s stock has an RSI of 46.35. Register for free on
Equity Research Institute and access the latest research on BIOC
at:
https://www.EquityResearchInstitute.com/reports?keyword=BIOC
Novadaq Technologies Inc.'s stock finished Thursday's session
0.61% lower at $13.11. A total of
0.14 million shares were traded, which was below its three months
average volume of 0.54 million shares. Over the previous three
months and since the beginning of 2015, Novadaq Technologies Inc.'s
shares have declined 19.07% and 21.12%, respectively. However, the
stock has surged 16.95% in the last one month. The company's shares
are trading above their 50-day moving average by 17.71%. Novadaq
Technologies Inc.'s stock has an RSI of 74.39. The complete
research on NVDQ is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=NVDQ
On Thursday, shares in ICON Public Limited Co. ended the session
1.06% lower at $68.23. The stock
reported a trading volume of 0.41 million shares, below its three
months average volume of 0.53 million shares. Shares of the company
traded at a PE ratio of 22.22. Although ICON Public Limited Co.'s
shares have lost 0.89% in the previous three months, it has
advanced 0.92% in the last one month and 33.81% on YTD basis. The
company is trading 1.79% above its 50-day moving average and 11.23%
above its 200-day moving average. Moreover, shares of ICON Public
Limited Co. have an RSI of 52.08. Free in-depth research on ICLR is
available at:
https://www.EquityResearchInstitute.com/reports?keyword=ICLR
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com